Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AMNEAL PHARMACEUTICALS, INC. (AMRX) vs Kiniksa Pharmaceuticals International, plc (KNSA)

AMNEAL PHARMACEUTICALS, INC. and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. AMNEAL PHARMACEUTICALS, INC. and Kiniksa Pharmaceuticals International, plc are of similar size ($6.3B and $5.9B). AMNEAL PHARMACEUTICALS, INC. trades at the lower P/E: 39.5× against 70.2×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against 9.28%. Kiniksa Pharmaceuticals International, plc has the higher net margin (9.59% vs 5.05%) and the higher return on invested capital (48.9% vs 11.1%). Across the 20 metrics below, Kiniksa Pharmaceuticals International, plc leads on 14 and AMNEAL PHARMACEUTICALS, INC. on 6.

Valuation

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
P/E 39.54 70.17 20.14
P/S 2.02 6.93 2.25
P/B 191.09 8.90 1.90
Price to free cash flow n/m 31.84 16.54
EV/EBITDA 13.30 51.93 12.29
EV/Sales 2.84 6.30 2.56
Earnings yield 2.53% 1.43% (2.99%)
Free cash flow yield (0.18%) 3.14% 0.00%

Profitability

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
Gross margin 39.32% 89.82% 53.94%
Operating margin 14.56% 11.92% 0.00%
Net margin 5.05% 9.59% 0.00%
Free cash flow margin (0.37%) 21.74% 0.00%
Return on equity (395.84%) 14.04% (0.40%)
Return on assets 4.37% 10.36% (3.32%)
Return on invested capital 11.05% 48.87% 0.00%

Growth

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 9.28% 58.85% 10.01%
EPS growth (last fiscal year) 157.89% 225.00% —
Revenue growth, 5-year CAGR 8.66% — 6.74%
Net income growth, 5-year CAGR (4.57%) 0.00% 0.00%

Health

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
Debt to equity 80.86 0.00 0.05
Current ratio 2.20 3.90 2.31
Net debt to EBITDA 3.62 (5.26) 0.85

Dividend

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
Dividend yield 0.27% — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AMRX KNSA Drug Manufacturers Specialty & Generic median
Market cap 6.32b 5.90b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack